atagabalin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels. It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results.   Wikipedia

Chemistry

  • SMILES: C[C@H]1CC(CN)(CC(=O)O)C[C@@H]1C
  • InChIKey: IUVMAUQEZFTTFB-YUMQZZPRSA-N
  • Mol. Mass: 185.27
  • ALogP: 1.47
  • ChEMBL Molecule:
    atagabalin  
More Chemistry

Pharmacology

Alternative names

(1-aminomethyl-3,4-dimethylcyclopentyl)acetic acid | atagabalin | pd0200390 | pd 0200390 | pd-0200390

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Sleep Disorders, Intrinsic (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue